| Zacks Company Profile for Interpace Biosciences, Inc. (IDXG : OTC) |
|
|
| |
| • Company Description |
| Interpace Biosciences Inc. is enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services include molecular diagnostic tests, bioinformatics, and pathology services. Pharma services provide pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. Interpace Biosciences Inc., formerly known as INTERPACE DIAGN, is based in PARSIPPANY, NJ.
Number of Employees: 111 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.75 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 5,179 shares |
| Shares Outstanding: 4.41 (millions) |
| Market Capitalization: $3.29 (millions) |
| Beta: 0.73 |
| 52 Week High: $3.54 |
| 52 Week Low: $0.44 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-4.42% |
-8.47% |
| 12 Week |
-17.17% |
-31.91% |
| Year To Date |
-72.36% |
-73.67% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
WATERVIEW PLAZA SUITE 310 2001 ROUTE 46
-
PARSIPPANY,NJ 07054
USA |
ph: 855-776-6419
fax: 862-207-7820 |
info@interpace.com |
http://www.interpace.com |
|
|
| |
| • General Corporate Information |
Officers
Thomas W. Burnell - Chief Executive Officer; President and Director
Christopher McCarthy - Chief Financial Officer
Stephen J. Sullivan - Director
Joseph Keegan - Director
Vijay Aggarwal - Director
|
|
Peer Information
Interpace Biosciences, Inc. (CHCR)
Interpace Biosciences, Inc. (ESRX)
Interpace Biosciences, Inc. (MYDP)
Interpace Biosciences, Inc. (COR)
Interpace Biosciences, Inc. (GBCS)
Interpace Biosciences, Inc. (LAXAF)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 46062X303
SIC: 3841
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/01/25
|
|
Share - Related Items
Shares Outstanding: 4.41
Most Recent Split Date: 1.00 (0.10:1)
Beta: 0.73
Market Capitalization: $3.29 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/01/25 |
|
|
|
| |
